Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ARNT | P27540 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627427 | 0.79 | ABCG2 (0.50) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5962635 | 0.79 | ALDH1A1 (0.62) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18797338 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9402434 | 0.77 | GRM4 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL9402383 | 0.76 | RAB9A (0.57) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15954532 | 0.75 | MAPT (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6643061 | 0.75 | NPC1 (0.59) | MAPTALDH1A1NPC1RAB9AHTT | |
| SCHEMBL8835541 | 0.74 | GRM4 (0.50) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16638713 | 0.74 | GRM4 (0.58) | MAPTALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL25432578 | 0.72 | MAPT (0.58) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115623-B2 | PDE IV inhibitors | ASKA PHARMACEUTICALS CO., LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040176365-A1 | Pde IV inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1403270-A1 | PDE IV INHIBITORS | Grelan Pharmaceutical Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176365-A1 | Pde IV inhibitors | PDE3B, PDE3A, PDE2A | VCAM1 3317/4885MAPT 4416/4885ALDH1A1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.